Crinecerfont enables glucocorticoid dose reductions while maintaining/improving androstenedione in paediatric patients with congenital adrenal hyperplasia: subgroup analyses from CAHtalyst™ paediatric. Read more about Crinecerfont enables glucocorticoid dose reductions while maintaining/improving androstenedione in paediatric patients with congenital adrenal hyperplasia: subgroup analyses from CAHtalyst™ paediatric.